Poseida Therapeutics Balance Sheet Health
Financial Health criteria checks 5/6
Poseida Therapeutics has a total shareholder equity of $60.8M and total debt of $58.8M, which brings its debt-to-equity ratio to 96.7%. Its total assets and total liabilities are $298.7M and $237.9M respectively.
Key information
96.7%
Debt to equity ratio
US$58.80m
Debt
| Interest coverage ratio | n/a |
| Cash | US$237.81m |
| Equity | US$60.82m |
| Total liabilities | US$237.87m |
| Total assets | US$298.69m |
Recent financial health updates
No updates
Recent updates
Financial Position Analysis
Short Term Liabilities: 2RZ's short term assets ($254.3M) exceed its short term liabilities ($102.4M).
Long Term Liabilities: 2RZ's short term assets ($254.3M) exceed its long term liabilities ($135.4M).
Debt to Equity History and Analysis
Debt Level: 2RZ has more cash than its total debt.
Reducing Debt: 2RZ's debt to equity ratio has increased from 71.7% to 96.7% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable 2RZ has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: 2RZ is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 7.4% per year.